Comparative Pharmacology
Head-to-head clinical analysis: FML S versus LOTRISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML S versus LOTRISONE.
FML-S vs LOTRISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production. This results in decreased inflammation, edema, and immune cell infiltration. Sulfacetamide is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking folate synthesis and bacterial growth.
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
1-2 drops of 0.1% ophthalmic suspension into the conjunctival sac every 4 hours; may increase to every 2 hours in severe inflammation.
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
None Documented
None Documented
2.8-3.5 hours; prolonged to 8-12 hours in renal impairment or in neonates
Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis.
Renal (65-75% as unchanged drug and metabolites), biliary/fecal (15-25%)
Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites).
Category C
Category C
Ophthalmic Antibiotic/Corticosteroid Combination
Topical Antifungal/Corticosteroid Combination